← Back to Search

Muscle Assessment Score for Liver Transplant Outcomes

N/A
Recruiting
Led By Elizabet Carey, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
All patients with end-stage liver disease undergoing evaluation for liver transplantation
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial is looking at how well a muscle assessment score can predict adverse outcomes in people who need a liver transplant.

Who is the study for?
This trial is for adults with end-stage liver disease who are being evaluated for a liver transplant and can safely undergo an MRI. It's not suitable for those who have conditions that make MRI scans unsafe for them.
What is being tested?
The study is looking at how muscle composition, measured by a special score from MRI images called MAsS, might predict complications or outcomes in people waiting for liver transplants.
What are the potential side effects?
Since this study uses MRIs to assess muscle composition and doesn't involve medication or invasive procedures, there aren't direct side effects related to the intervention.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am being evaluated for a liver transplant due to end-stage liver disease.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Adverse outcomes
MAsS changes while waiting for liver transplant
Muscle assessment score (MAsS)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Define MAsS cut-point at transplant evaluation to identify those with high risk for adverse outcomesExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,362 Previous Clinical Trials
3,065,861 Total Patients Enrolled
4 Trials studying Sarcopenia
182 Patients Enrolled for Sarcopenia
Amra Medical ABIndustry Sponsor
2 Previous Clinical Trials
161 Total Patients Enrolled
1 Trials studying Sarcopenia
150 Patients Enrolled for Sarcopenia
Elizabet Carey, MDPrincipal InvestigatorMayo Cinic
~19 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top